primary liver cancer
Conditions
Interventions
Laparoscopic portal territory anatomical hepatectomy group:High-quality thin-slice CT or MR image reconstruction of three-dimensional visualization models guide preoperative planning and surgery.The s
Conventional Laparoscopic Non-anatomical Hepatectomy:High-quality thin-slice CT or MR image guide preoperative planning and surgery. The specific surgical plan is based on the principle of complete re
Sponsors
Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients with primary liver cancer diagnosed clinically before surgery (tumor size =2cm and =5cm, diagnostic criteria: Primary Liver Cancer Diagnosis and Treatment Guidelines 2021); (2) No major portal vein, hepatic vein, or inferior vena cava invasion was found in the imaging data, and no distant metastasis was found. The tumor can be completely removed under laparoscopy; (3) Patients can tolerate anatomical liver resection, indocyanine green retention rate at 15 minutes (ICG-R15) <20%, and sufficient residual liver volume; (4) Child-Pugh classification of liver function is grade A or B; (5) Age is between 18-70 years old; (6) Clinical case data is complete; (7) Voluntarily participate in the study and informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with basic diseases that cannot tolerate surgery (such as severe heart, lung, brain, and kidney dysfunction); (2) Patients who underwent open liver resection; (3) Unclear diagnosis of primary liver cancer before surgery; (4) The tumor diameter is 5 cm before surgery, and there are cancer emboli in the portal vein trunk and branches, hepatic duct and branches, hepatic vein trunk and branches, and inferior vena cava; (5) ICGR-15>20%, insufficient residual liver volume (occupying <35% of the standard liver volume); (6) Child-Pugh classification of liver function is grade C before surgery; (7) Patients who have undergone surgery, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), or targeted therapy for primary liver cancer before surgery; (8) Planned pregnancy, unplanned pregnancy, and pregnant women; (9) Patients with diseases that the researchers believe are not suitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Perioperative prognosis; | — |
Countries
China
Contacts
Public ContactLiang Xiao
Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed